DDInter458 DDInter448
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) PLK4
PLK4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) CDK7
CDK7 {u} (Gene) is bound by {v} (Compound) Crizotinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Cyclosporine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Crizotinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) KIF18B
KIF18B {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) AURKA
AURKA {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Cyclosporine (Compound) downregulates PLK4 (Gene) and PLK4 (Gene) is bound by Crizotinib (Compound)
Cyclosporine (Compound) upregulates CDK7 (Gene) and CDK7 (Gene) is bound by Crizotinib (Compound)
Cyclosporine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Crizotinib (Compound)
Cyclosporine (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is upregulated by Crizotinib (Compound)
Cyclosporine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Crizotinib (Compound)
Cyclosporine (Compound) downregulates KIF18B (Gene) and KIF18B (Gene) is downregulated by Crizotinib (Compound)
Cyclosporine (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Crizotinib (Compound)
Cyclosporine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Cyclosporine (Compound) downregulates AURKA (Gene) and AURKA (Gene) is bound by Crizotinib (Compound) and AURKA (Gene) is downregulated by Crizotinib (Compound)